Bonspri Solution for Injection

Composition Ofatumumab (20mg/0.4ml)
Rx Prescription Required
Pack prefilled syringe of 0.4 ml Solution for Injection
Storage None
Chemical Class Monoclonal antibody (mAb)
Action Class Anti-CD20 Monoclonal Antibodies
Habbit Forming
Manufacturer Novartis India Ltd
Manufacturer address Sandoz House, Shiv Sagar Estate, Worli Mumbai -400 018, India

Bonspri Solution for Injection is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS). It works by targeting and depleting B cells, a type of white blood cell involved in the immune system’s attack on the nervous system in MS. It helps slow disease progression and reduce the number of relapses.

Bonspri Solution for Injection is administered subcutaneously (under the skin). Administer the medicine as prescribed and do not skip any doses, as consistency helps maintain its effectiveness. To get the most benefit, follow up with your doctor regularly, stay up to date with vaccinations before starting treatment, and monitor for any signs of infection.

Common side effects of Bonspri Solution for Injection include injection-site reactions such as redness, swelling, or pain, as well as flu-like symptoms like fever, headache, chills, and fatigue, especially after the first doses. These symptoms usually improve with time. Some people may experience upper respiratory infections or urinary tract infections. Staying hydrated and practicing good hygiene can help reduce the risk. If side effects become severe or do not go away, consult your doctor for guidance.

Since Bonspri Solution for Injection lowers certain immune cells, it can increase the risk of infections, including serious ones like hepatitis B reactivation or upper respiratory infections. Before starting treatment, your doctor may check for infections and ensure your vaccinations are up-to-date. Avoid live vaccines while on treatment with Bonspri Solution for Injection, as they may not be safe. If you develop signs of infection, such as a persistent fever, sore throat, or unusual tiredness, seek medical advice promptly. People with a weakened immune system or a history of hepatitis B should discuss risks with their doctor before starting Bonspri Solution for Injection.

Pregnant or breastfeeding women should consult their doctor before using Bonspri Solution for Injection, as it may harm the baby. Both men and women should use effective contraception during treatment to prevent pregnancy. Bonspri Solution for Injection is a strong medication, so always follow your doctor’s advice and report any concerns promptly to ensure the best results while minimizing risks.

Treatment of Relapsing forms of multiple sclerosis (MS)

Your doctor or nurse will guide you how to use this medicine.

Bonspri Solution for Injection is a medicine that targets and removes B cells, a type of immune cell that plays a role in multiple sclerosis (MS). It binds to a protein called CD20 on B cells, marking them for destruction. This helps reduce inflammation, lower the number of relapses, and slow down the damage to the nervous system. The treatment keeps B cells under control while allowing some to recover over time.

Q: What if you forget to take Bonspri Solution for Injection?
A: If you missed a dose of Bonspri Solution for Injection, administer it as soon as possible without waiting until the next scheduled dose. Subsequent doses should be administered at the recommended intervals.

Administer Bonspri Solution for Injection as prescribed to maintain effectiveness. Set reminders if needed.

Report any signs of infection, such as fever, cough, or sore throat, to your doctor.

Get necessary vaccines at least 4 weeks before starting treatment, and avoid live vaccines during treatment.

Use birth control during treatment and for at least 6 months after stopping.

Drink plenty of water and rest to ease flu-like side effects.

Follow up regularly with your doctor to monitor progress and manage side effects early.

In Treatment of Relapsing forms of multiple sclerosis (MS)

In individuals with relapsing forms of multiple sclerosis (MS), Bonspri Solution for Injection helps prevent relapses and slows the disability progression. It also helps reduce inflammation, decrease the frequency of flare-ups, minimize nerve damage, and improve long-term outcomes. When used as prescribed, Bonspri Solution for Injection helps patients maintain their independence, stay active, and improve their overall quality of life.

Headache

Fever

Muscle pain

Chills

Tiredness

Injection site reactions (pain, swelling, redness)

Upper respiratory tract infection

Urinary tract infection

Alcohol:CONSULT YOUR DOCTOR

It is not known whether it is safe to consume alcohol with Bonspri Solution for Injection. Please consult your doctor.

Pregnancy:CONSULT YOUR DOCTOR

Bonspri Solution for Injection may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.

Breast feeding:CONSULT YOUR DOCTOR

Information regarding the use of Bonspri Solution for Injection during breastfeeding is not available. Please consult your doctor.

Driving:SAFE

Bonspri Solution for Injection does not usually affect your ability to drive.

Kidney:CONSULT YOUR DOCTOR

There is limited information available on the use of Bonspri Solution for Injection in patients with kidney disease. Please consult your doctor.

Liver:CONSULT YOUR DOCTOR

There is limited information available on the use of Bonspri Solution for Injection in patients with liver disease. Please consult your doctor.

Chabner BA, Barnes J, Neal J, et al. Targeted Therapies: Tyrosine Kinase Inhibitors, Monoclonal Antibodies, and Cytokines. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 12th ed. New York, New York: McGraw-Hill Medical; 2011. pp. 1747-48.
Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. p. 1011.
Ofatumumab [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2024. [Accessed 03 Apr. 2025] (online) Available from: View
Ofatumumab [Summary of Product Characteristics]. Dublin 4, Ireland: Novartis Europharm Limited; 2021. [Accessed 03 Apr. 2025] (online) Available from: View
Ofatumumab [Professional Information]. Johannesburg, South Africa: Novartis South Africa (Pty) Ltd.; 2023. [Accessed 03 Apr. 2025] (online) Available from: View